# Discovery of novel broad-spectrum coronavirus inhibitors

> **NIH NIH U19** · UNIVERSITY OF TEXAS MED BR GALVESTON · 2022 · $2,888,994

## Abstract

PROJECT 2 – ABSTRACT
The goal of this project is to discover novel broad-spectrum coronavirus inhibitors. We will identify new broad-
spectrum coronavirus inhibitors of viral replication using a cell-based approach. We will achieve the goal by
pursuing three aims. (i) Screen and identify novel compounds for broad-spectrum coronavirus inhibition. We will
screen and identify inhibitors of viral replication using SARS-CoV-2, MERS-CoV, and 229E infection assays.
UTMB has developed an single-cycle infection system for SARS-CoV-2 that can be used for HTS campaign at
BSL2. In this application, we will expand this system to MERS-CoV. We will also develop a reporter 229E
coronavirus for antiviral screen. (ii) Develop tool compounds, determine target protein, and optimize molecules.
(iii) Evaluate lead compounds in relevant in vitro and in vivo models and select Development Candidate for IND-
enabling studies. The proposed cell-based approach may discover novel antiviral targets that may not be
tractable for target-based antiviral approach.

## Key facts

- **NIH application ID:** 10514153
- **Project number:** 1U19AI171413-01
- **Recipient organization:** UNIVERSITY OF TEXAS MED BR GALVESTON
- **Principal Investigator:** VINEET D MENACHERY
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $2,888,994
- **Award type:** 1
- **Project period:** 2022-05-16 → 2025-03-24

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10514153

## Citation

> US National Institutes of Health, RePORTER application 10514153, Discovery of novel broad-spectrum coronavirus inhibitors (1U19AI171413-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10514153. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*